# Sana Biotechnology Inc. (SANA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.85, market value $1.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Sana Biotechnology Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 7.5×**. The shares trade at 7.5× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -11.7%** (5-yr avg -33.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -151.8%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 17.2%**. Earnings per share rose 17.2%.

## Financial health
- **Current ratio: 1.89** (quick 1.89). Current assets cover the next year's liabilities 1.89 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Sana Biotechnology Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 29.2%** (YTD -5.4%, 3-mo 43.7%). The shares are up 29.2% over twelve months including dividends.
- **From 52-week high: -41.2%** (47.5% above the low). Trading 41% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 2.40** (volatility 85%). Beta of 2.40 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SANA · Page: https://foliofundamentals.com/stocks/sana

Not investment advice.